October 2, 2025

Cirrus Therapeutics Announces $11 million Seed Round to Advance Novel Ocular Gene Therapy Designed to Potentially Reverse Crucial Underlying Cause of Dry AMD

Cirrus Therapeutics, an ocular immunology-focused biotech, announced today the close of an $11 million seed financing to advance its pipeline of gene and cell therapies aimed at improving quality of…

Read more
October 2, 2025

Exclusive: Gene therapy startup launches with $11M to tackle aging disease of the eye

Cirrus Therapeutics has raised an $11 million seed round toward its bet that altering the immune function of the eye using gene therapy can slow or potentially stop aging-related conditions…

Read more
August 5, 2025

Uveitis in Adults: A Review

Uveitis is characterized by inflammation of the uvea and primarily affects adults aged 20 to 50 years. For noninfectious anterior uveitis, corticosteroid eyedrops are first-line treatment. For posterior noninfectious uveitis,…

Read more
April 25, 2025

CEO Dr. Kai Chan Presents at Investing in Cures Summit 2025

The Foundation Fighting Blindness and the Retinal Degeneration Fund (RD Fund) hosted their annual Investing in Cures Summit (ICS) on March 21 and 22, 2025 in Tampa to highlight the…

Read more
July 14, 2024

Treating age-related macular degeneration with Drs. Kai Chan and Andrew Dick (Cirrus Therapeutics)

The “Aging Well Podcast” is about, well…aging. It’s for people of all ages who are interested in aging successfully. The topics include the Spiritual, Physical, Intellectual, Emotional, and Social dimensions…

Read more
June 24, 2024

Cambridge startup aims at age-related eye disease with gene therapy

A Cambridge-based therapeutics company is working on a gene therapy aimed at a key protein in the eye that it says will help older adults against macular degeneration

Read more